Atazanavir Signature I50L Resistance Substitution Accounts for Unique Phenotype of Increased Susceptibility to Other Protease Inhibitors in a Variety of Human Immunodeficiency Virus Type 1 Genetic Backbones

Gelijkaardige items

• Molecular Basis for Increased Susceptibility of Isolates with Atazanavir Resistance-Conferring Substitution I50L to Other Protease Inhibitors
  door: Yanchunas, Joseph, et al.
  Gepubliceerd in: (2005)
• X-Ray Crystal Structures of Human Immunodeficiency Virus Type 1 Protease Mutants Complexed with Atazanavir
  door: Klei, Herbert E., et al.
  Gepubliceerd in: (2007)
• Structural and Thermodynamic Basis of Amprenavir/Darunavir and Atazanavir Resistance in HIV-1 Protease with Mutations at Residue 50
  door: Mittal, Seema, et al.
  Gepubliceerd in: (2013)
• Activities of Atazanavir (BMS-232632) against a Large Panel of Human Immunodeficiency Virus Type 1 Clinical Isolates Resistant to One or More Approved Protease Inhibitors
  door: Colonno, Richard J., et al.
  Gepubliceerd in: (2003)
• Effects of Minocycline and Valproic Acid Coadministration on Atazanavir Plasma Concentrations in Human Immunodeficiency Virus-Infected Adults Receiving Atazanavir-Ritonavir
  door: DiCenzo, Robert, et al.
  Gepubliceerd in: (2008)